Detailed explanation of the instruction manual and usage of Dali Leisheng (Keweike)

Daridorexant (Daridorexant) is a new type of dual orexin receptor antagonist (DORA, Dual Orexin Receptor Antagonist). It is mainly used to treat insomnia in adults, especially for patients who have difficulty falling asleep or maintaining sleep. The drug blocks the orexin receptors OX1R and OX2R, inhibits the awakening signal of the orexin nervous system, helps patients fall asleep more naturally, and maintain a stable sleep state. Compared with traditional sedative-hypnotics (such as benzodiazepines), it is less likely to cause addiction and drug resistance, and is considered to be a safer and more circadian rhythm sleep aid drug. The following will provide a detailed explanation of the contents of the drug instructions, usage, adverse reactions and precautions.

The trade name of DaliRasen is Quviviq, which was approved for marketing in Europe and the United States in 2022 for the treatment of adult insomnia. Indications mainly include prolonged sleep onset latency (difficulty falling asleep) and frequent awakenings during the night (difficulty maintaining sleep). The mechanism of action of DaliRazen has nothing to do with GABA receptors, but regulates wakefulness and sleep balance by antagonizing the orexin system, fundamentally improving the problem of insomnia. It is one of the more cutting-edge therapeutic drugs in the world in recent years. Studies have shown that DaliRasen can effectively shorten the time it takes to fall asleep, extend the total sleep time, and improve daytime function the next day without causing serious morning drowsiness or cognitive impairment.

Dalilaysan is usually taken as oral tablets, and the commonly recommended dose is 25mg every night. In some cases, it can be adjusted to 50mg according to the specific conditions of the patient. It is recommended to take it within 30 minutes before going to bed to ensure that you have at least 7 hours of complete sleep after taking the medicine. The medicine should not be taken with a large amount of food, especially high-fat meals, as this will delay the onset of action of the medicine and affect the speed of falling asleep. It is not recommended to use this drug in combination with other central nervous system depressants to avoid increasing the sedative effect. In addition, it should not be taken during the day, nor should the dose be increased arbitrarily to avoid the risk of excessive sedation or drowsiness the next day. For patients with mild or moderate impairment of liver function, the dose can be adjusted appropriately based on physician evaluation; patients with severe liver impairment or those currently using strong CYP3A4 inhibitors should use it with caution or avoid use.

The overall safety of DaliRasen is good, and the incidence of adverse reactions is lower than that of traditional sleeping pills. Common adverse reactions include headache, drowsiness, fatigue, occasional vivid dreams, abnormal nighttime awakening, etc. Symptoms are generally mild and can gradually reduce as the treatment time increases. Some patients may experience brief morning drowsiness during the initial period of medication, but this will not significantly affect daytime activities. Unlike benzodiazepines, Dalitrazolin does not inhibit the respiratory center, has less cognitive impact on the elderly, and has no obvious dependence or withdrawal reactions, so it is suitable for long-term standardized use. Clinical trial results show that after using DaliRazo for more than 3 months, its efficacy remains stable and there is no obvious increase in tolerance.

During the use of DaliRasen, patients should avoid drinking alcohol and using other sedative drugs at the same time to avoid additive central depressant effects. Additionally, medications should not be taken before driving or operating machinery, and ensure you have adequate sleep before engaging in high-risk activities. For pregnant and lactating women, clinical data are currently limited and strict evaluation by a doctor is required before use. There is insufficient safety data for minors and use is not recommended. If you need to stop taking the drug, you generally don’t need to gradually reduce the dose. You can stop taking it directly. Obvious rebound insomnia is less likely to occur after stopping the drug.

In general, DaliRasen is a new sleep-aid drug with a clear target, stable onset, and high safety, and is suitable for standardized use by patients with long-term insomnia. Its unique mechanism avoids many adverse reactions of traditional sleeping pills and provides a new direction and better choice for the treatment of insomnia. In practical applications, doctors should formulate individualized medication plans based on the patient's specific condition, concomitant medications, and living habits to obtain the best therapeutic effect.

Reference materials:https://www.drugs.com/